Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target raised by Leerink Partners from $80.00 to $88.00 in a report released on Monday,Benzinga reports. Get Crinetics Pharmaceuticals alerts:Get Our Latest Report on CRNXCrinetics Pharmaceuticals Price PerformanceShares of CRNX opened at $43.51 on Monday. On average, equities analysts anticipate that Crinetics Pharmaceuticals will post -3.73 earnings per share for the current fiscal year. Crinetics Pharmaceuticals Company Profile(Get Free Report)Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. See AlsoReceive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.